



Innate Biologics and The University of Münster Medical Enter into Broad Multi-Year Collaboration Agreement, Expanding Scientific Resources with a Focus on Dermatological Therapeutics

The University, a pioneer in multiple skin-related discoveries, expands effort with Innate Biologics™ to focus on completion of global commercial applications for dermatological and other age-related inflammatory conditions

Münster, Germany and Philadelphia, US—June 21, 2019 Innate Biologics™ has entered into a multi-year collaboration agreement with one of Germany’s leading scientific and research institutes with a focus on skin applications. The collaboration will focus on the topical delivery of anti-inflammatory therapeutics using recombinant bacterial effectors – first discovered in Münster. Innate Biologics™, a US pioneer in the commercial application of bacterial effectors, has developed a first-of-kind recombinant protein platform, which specifically targets intracellular inflammatory signaling pathways using full-length, optimized and paired proteins. Both University of Münster and Innate Biologics hold issued, (and filed) Intellectual Property tied directly to the Collaboration Agreement.

Peter Mondics, CEO of Innate Biologics, commented: “Innate’s work with Münster over the last year has produced a series of clinical insights and pathways that point directly to targeted, novel, and anti-inflammatory biologics, all with a pronounced patient-friendly profile. The scale of therapeutic applications, left largely vacant for sufferers of certain widely-diagnosed conditions like Psoriasis and age-related inflammatory skin issues, makes this undertaking a broad and material differentiator in a very large market.”

Innate Biologics™ has assembled a worldwide scientific team and patent portfolio, focused on cell-penetrating bacterial effector polypeptides. In pre-clinical studies, treatment with a single Innate Biologics™ effector, resulted in clear/measurable down-regulation of multiple pro-inflammatory cytokine signaling pathways. Along with Innate Biologics™’ Patent Portfolio family comes the added capacity to modulate, and suppress immune-signaling pathways associated with a number of inflammatory conditions.

Innate Biologics™ is commercializing the ability of bacterial polypeptides to autonomously enter human host cells and suppress host inflammatory response. As part of its research effort, it is developing novel constructs based on these polypeptides for treatment of a range of disorders. The Innate Biologics™ effector proteins are being developed for oral, topical, intra-articular, and intravenous delivery to multiple body compartments and organ systems.

###

About Innate Biologics™

Innate Biologics™, a privately held company, focuses on therapeutics for targeting, treating, and preventing inflammation. Its first-of-kind, recombinant bacterial effector polypeptide platform, *Paired Protein Platform™* specifically targets intracellular inflammatory signaling pathways. Innate Biologics holds a growing Intellectual Property Catalogue, along with Collaboration Agreements coupled to worldwide exclusive rights for a range of anti-inflammatory proteins including: full-length/optimized recombinant proteins, paired proteins and protein transduction domains. www.innatebiologics.com

About University of Münster Medical

The University of Münster, is an internationally recognized leader in biomedical research bringing together scientists and clinicians from a range of departments including Mathematics and Computer Science institutes to comprehensively analyze findings into an innovative discovery research and teaching environment. More than 2,000 specialists combine their efforts to understand disease, explore biomedical principles, and develop novel tools for diagnosis and treatment. Recognized Faculties include: Biology, Physics, Chemistry and Pharmacy. www.medizin.uni-muenster.de/en/faculty-of-medicine/welcome/

This release contains “forward-looking statements” concerning the development of Innate Biologics, LLC’s products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will be commercially successful. Forward-looking statements are subject to risk, assumptions, and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Innate Biologics, LLC undertakes no obligation to update any forward-looking statements for any reason.